Asthma exacerbations and lung function in patients with severe or difficult-to-treat asthma - 06/10/15
| TENOR was funded by Genentech, Inc (South San Francisco, Calif) and Novartis Pharmaceuticals (East Hanover, NJ). |
|
| Disclosure of potential conflict of interest: W. J. Calhoun has consultant arrangements with Genentech, Inc. T. Haselkorn has consultant arrangements with Genentech, Inc. D. P. Miller has received consultant fees and fees for participation in review activities from Genentech, Inc and is employed by ICON Clinical Research. T. A. Omachi has received travel support from and is employed by Genentech, Inc and has stock/stock options with Roche. |
Vol 136 - N° 4
P. 1125 - octobre 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?

